BioNTech SE

BioNTech SE (BNTX) priced its initial public offering on Oct 11, 2019 at $15.00 per ADS, within its $15.00–$16.00 range, raising $150M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $3.39B. J.P. Morgan was lead-left underwriter, joined by UBS, Leerink Partners and Canaccord Genuity and others. Freshfields and Covington & Burling advised the company and Skadden, Arps and Davis Polk advised the underwriters.

BioNTech SE is a biotechnology company founded in 2008 that develops individualized immunotherapies for cancer and other diseases. It combines immunology research, therapeutic platforms, and patient profiling and bioinformatic tools to create treatments tailored to each patient's tumor.

Status

IPO

Ticker

BNTX

Exchange

Nasdaq Global Select

Priced

Oct 11, 2019

IPO price

$15.00 per ADS

Price range

$15.00–$16.00

Raised

$150M

Market cap at IPO price

$3.39B

First filed

Sep 9, 2019

Underwriters

J.P. Morgan, UBS, Leerink Partners, Canaccord Genuity, Wolfe Research, Kempen and Mirae Asset

Company counsel

Freshfields and Covington & Burling

Underwriters' counsel

Skadden, Arps and Davis Polk

Sector

Biotech & pharma

Country / state

Germany

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.